πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 2,432 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 7501415

Selective inhibitors of ERK protein kinase and uses thereof

Vertex Pharmaceuticals Incorporated Β· Granted Tue Mar 10 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 05 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7494988

Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease

Vertex Pharmaceuticals Incorporated Β· Granted Tue Feb 24 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 19 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7495014

Gyrase inhibitors and uses thereof

Vertex Pharmaceuticals Incorporated Β· Granted Tue Feb 24 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 19 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7491730

Compositions useful as inhibitors of GSK-3

Vertex Pharmaceuticals Incorporated Β· Granted Tue Feb 17 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 12 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7488727

Thiazole compounds useful as inhibitors of protein kinase

Vertex Pharmaceuticals Incorporated Β· Granted Tue Feb 10 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 05 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7485664

Inhibitors of TACE

Vertex Pharmaceuticals Incorporated Β· Granted Tue Feb 03 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 29 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7482002

Method of administering and using VEGF inhibitors for the treatment of prostate cancer

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 27 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 22 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7479274

Method of administering and using VEGF inhibitors for the treatment of pancreatic carcinom

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 20 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 15 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7479273

Method of administering and using VEGF inhibitors for the treatment of renal cell cancer

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 20 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 15 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7479272

Method of administering and using VEGF inhibitors for the treatment of breast cancer

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 20 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 15 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7479275

Method of administering and using VEGF inhibitors for the treatment of colorectal cancer

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 20 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 15 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7470776

Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof

The Board of Regents of the University of Oklahoma Β· Granted Tue Dec 30 2008 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 25 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7470700

Dipeptidyl peptidase inhibitors

Takeda Pharmaceutical Company Limited Β· Granted Tue Dec 30 2008 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 25 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7470790

Heteroaromatic selective inhibitors of neuronal nitric oxide synthase

Northwestern University Β· Granted Tue Dec 30 2008 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 25 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7468379

Inhibition of osteolytic lesions by SRC kinase inhibitors

The Board of Regents of the University of Texas System Β· Granted Tue Dec 23 2008 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 18 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7462612

Pyridine inhibitors of ERK2 and uses thereof

Vertex Pharmaceuticals Incorporated Β· Granted Tue Dec 09 2008 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 04 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7459453

Pyridazin-3(2H)-one derivatives as PDE4 inhibitors

Laboratories Almirall, S.A. Β· Granted Tue Dec 02 2008 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 27 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7456190

Compositions useful as protein kinase inhibitors

Vertex Pharmaceuticals Incorporated Β· Granted Tue Nov 25 2008 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 20 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7452873

Inhibitors of GSK-3 and uses thereof

Vertex Pharmaceuticals Incorporated Β· Granted Tue Nov 18 2008 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 13 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7445794

Methods for treating human proliferative diseases, with a combination of fatty acid metabo

The Regents of the University of Colorado Β· Granted Tue Nov 04 2008 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 30 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7446199

Compositions useful as inhibitors of protein kinases

Vertex Pharmaceuticals Incorporated Β· Granted Tue Nov 04 2008 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 30 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7442718

Inhibitors of aspartyl protease

Vertex Pharmaceuticals Incorporated Β· Granted Tue Oct 28 2008 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 23 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7442790

Caspase inhibitors and uses thereof

Vertex Pharmaceuticals Incorporated Β· Granted Tue Oct 28 2008 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 23 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7439249

Inhibitors of phosphatases

Vertex Pharmaceuticals Incorporated Β· Granted Tue Oct 21 2008 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 16 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted